From a mechanistic standpoint, MAFLD may promote gallstone formation through several pathways: hepatic insulin resistance activates sterol regulatory element-binding protein-2 (SREBP-2), enhancing cholesterol synthesis and leading to cholesterol-supersaturated bile (15, 16). The gene discussed is SREBF2; the disease is Insulin resistance.